pbt2
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00471211)
Timeline
Indications
Mechanism of action
- Superoxide dismutaseINHIBITOR
SOD1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pbt2
- pbt2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02249728 | Phase 1 | Jun 1, 2014 | Alterity Therapeutics |
| NCT02107313 | Phase 1 | May 1, 2014 | Alterity Therapeutics |
| NCT02109497 | Phase 1 | May 1, 2014 | Alterity Therapeutics |
| NCT01590888 | Phase 2 | Apr 1, 2012 | Alterity Therapeutics, Johns Hopkins University |
| NCT00471211 | Phase 2 | Dec 1, 2006 | Alterity Therapeutics, Uppsala University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alterity Therapeutics | For profit | 5 | 5 | 2 | 2006 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Uppsala University | Academic/Hospital | 1 | 0 | 1 | 2006 |
3 organizations
Page 1 / 1